Thursday, 15 October 2026European Markets

SPAREBANKEN ØST And SPBK 1 NORDMØRE Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - SPAREBANKEN ØST (SPOG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SPAREBANKEN ØST (SPOG.OL) kr51.80 7.55% 6.25%
SPBK 1 NORDMØRE (SNOR.OL) kr135.00 3.94% 6.44%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPAREBANKEN ØST (SPOG.OL)

7.55% Forward Dividend Yield and 6.25% Return On Equity

Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; mortgages on homes; and debenture financing for second-hand cars, as well as services in the areas of financing, savings and investment, and money-transfer. It also distributes insurance, fund shares, interest rate hedging, and currency, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr6.62.

PE Ratio

SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.82. Meaning, the purchaser of the share is investing kr7.82 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.25%.

More news about SPAREBANKEN ØST.

2. SPBK 1 NORDMØRE (SNOR.OL)

3.94% Forward Dividend Yield and 6.44% Return On Equity

SpareBank 1 Nordmøre provides various banking services in Norway. The company offers savings and deposit accounts; car, motorcycle, boat, and construction loans; and mortgages. It also provides business insurance products, which include liability, auto, mortgage, operating loss, asset, commercial, and project insurance products; personal insurance products, such as life, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. In addition, the company offers bank guarantees, trade credit products, and operating credit products for agriculture, as well as factoring, leasing, and repayment products and services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre is a subsidiary of SpareBank 1 Gruppen AS.

Earnings Per Share

As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr9.31.

PE Ratio

SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 14.5. Meaning, the purchaser of the share is investing kr14.5 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.44%.

More news about SPBK 1 NORDMØRE.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com